CG
VRTX icon

Colony Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Colony Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$37.6M Sell
108,145
-2,060
-2% -$720K 0.56% 36
2023
Q2 		$38.8M Sell
110,205
-2,241
-2% -$755K 0.55% 39
2023
Q1 		$35.4M Buy
112,446
+18,451
+20% +$5.53M 0.52% 42
2022
Q4 		$27.1M Buy
93,995
+7,769
+9% +$2.37M 0.38% 63
2022
Q3 		$25M Buy
86,226
+12,368
+17% +$3.56M 0.44% 50
2022
Q2 		$20.8M Buy
73,858
+9,273
+14% +$2.48M 0.36% 63
2022
Q1 		$16.9M Buy
+64,585
New +$15.3M 0.25% 96
2021
Q1 		– Sell
-1,421
Closed -$336K – 789
2020
Q4 		$336K Sell
1,421
-982
-41% -$225K 0.01% 583
2020
Q3 		$654K Sell
2,403
-55
-2% -$15.2K 0.02% 429
2020
Q2 		$714K Sell
2,458
-18
-0.7% -$4.88K 0.02% 394
2020
Q1 		$589K Sell
2,476
-189
-7% -$43.4K 0.02% 419
2019
Q4 		$584K Buy
2,665
+7
+0.3% +$1.42K 0.01% 498
2019
Q3 		$450K Sell
2,658
-54
-2% -$9.55K 0.01% 507
2019
Q2 		$497K Sell
2,712
-3
-0.1% -$524 0.02% 506
2019
Q1 		$499K Buy
+2,715
New +$501K 0.02% 397
2016
Q1 		– Sell
-567
Closed -$71K – 638
2015
Q4 		$71K Sell
567
-70
-11% -$8.45K 0.01% 450
2015
Q3 		$66K Buy
637
+567
+810% +$72.8K 0.01% 443
2015
Q2 		$9K Hold
70
– – ﹤0.01% 609
2015
Q1 		$8K Hold
70
– – ﹤0.01% 600
2014
Q4 		$8K Hold
70
– – ﹤0.01% 611
2014
Q3 		$8K Hold
70
– – ﹤0.01% 639
2014
Q2 		$7K Hold
70
– – ﹤0.01% 584
2014
Q1 		$5K Hold
70
– – ﹤0.01% 668
2013
Q4 		$5K Buy
+70
New +$4.88K ﹤0.01% 584

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group's VRTX Position: Q3 2023 in Review

Colony Group reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q3 2023, selling an estimated $720K and leaving 108,145 shares worth $37.6M. The position accounts for 0.56% of the portfolio, ranked #36.

Colony Group first reported a position in VRTX in Q4 2013 and has held it in 24 quarters since. The position peaked at $38.8M in Q2 2023. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Colony Group held 108,145 shares of Vertex Pharmaceuticals worth $37.6M as of Q3 2023.
  • Colony Group sold 2,060 Vertex Pharmaceuticals shares in Q3 2023, an estimated $720K.
  • Vertex Pharmaceuticals made up 0.56% of Colony Group's portfolio in Q3 2023, its #36 holding.
  • Colony Group first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 24 quarters since.
  • Colony Group's Vertex Pharmaceuticals position peaked at $38.8M in Q2 2023.
  • 1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.